| Literature DB >> 27123332 |
Patrick Jones1, Bhavan Prasad Rai2, Bhaskar K Somani3.
Abstract
INTRODUCTION: Management of urolithiasis in a solitary functioning kidney can be clinically challenging. The aim of this article was to review the outcomes of URS for patients with stone disease in a solitary kidney and critically appraise the existing evidence and outcome reporting standards.Entities:
Keywords: calculi; laser; solitary kidney; stone; ureteroscopy
Year: 2016 PMID: 27123332 PMCID: PMC4846718 DOI: 10.5173/ceju.2016.663
Source DB: PubMed Journal: Cent European J Urol ISSN: 2080-4806
Figure 1PRISMA flowchart of literature search.
Summary of study information and patient demographics (ND = not documented, *confirmed by dimercaptosuccinic acid renography)
| Author | Journal | Year | Country | Level of evidence | Number of patients | Male: Female | Mean age +/- 1 SD (years) | Mean BMI +/-1 SD (kg/m2) | Mean pre-operative creatinine +/- SD (mg/dL) | Aetiology of solitary kidney | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contra-lateral nephrectomy | Congenital agenesis | Non-functioning contra-lateral kidney * | ||||||||||
| Atis | Urology | 2013 | Turkey | 4 | 24 | 14:10 | 44.41 +/-2.15 | ND | 1.54 +/-0.55 | 9 | 5 | 10 |
| Yuruk | Journal of Endourology | 2014 | Turkey | 4 | 18 | 9:9 | 47.1 +/-13.8 | 25.5 +/-4.2 | 1.38 +/-0.4 | ND | ND | ND |
| Gao | Journal of Endourology | 2014 | China | 4 | 45 | 29:16 | 51.04 +/-1.67 | ND | 1.29 +/-0.61 | 13 | 7 | 25 |
| Giusti | World Journal of Urology | 2014 | Italy | 4 | 29 | 17:12 | 55.7 +/-12.3 | 25.1 +/-2.5 | 1.5 +/-0.6 | 14 | 6 | 9 |
Baseline values of stones (ND – no data)
| Study | Laterality, left/right | Mean stone size +/-1 SD (mm) | Stone location, n (%) | Stone composition, n (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Renal Pelvis | Upper Pole | Middle Pole | Lower Pole | Multiple | Calcium Oxalate | Uric Acid | Struvite | Mixed | |||
| Atis et al. 2013 | ND | 19.83 +/-5.9 | 9 (25) | 6 (16.66) | 7 (19.44) | 14 (38.88) | ND | 18 (75) | 3 (12.5) | 3 (12.5) | 0 |
| Yuruk et al. 2014 | 9/9 | 16 +/-2.6 | 7 | 11 | ND | ND | ND | ND | ND | ||
| Gao et al. 2014 | 23/22 | 18.4 +/-1.9 | 13 (28.88) | 1 (2.22) | 1 (2.22) | 10 (22.22) | 20 (44.44) | ND | ND | ND | ND |
| Giusti et al. 2014 | ND | 13 +/-4.0 | 18 (62.1) | 2 (6.9) | 3 (10.3) | 6 (20.7) | ND | 15 (51.7) | 2 (6.9) | 4 (13.8) | 8 (27.6) |
Inclusion/Exclusion Criteria for studies (ND – no description)
| Study | Inclusion Criteria | Exclusion Criteria |
|---|---|---|
| Atis et al. 2013 | Failed SWL | ND |
| Yuruk et al. 2014 | Functional or anatomically single kidneys | ND |
| Gao et al. 2014 | Failed SWL | Severe hydronephrosis |
| Giusti et al. 2014 | Age >18 years | Pregnancy |
Outcomes of the included studies (ND – not documented, AUR – acute urinary retention)
| Author | Mean operating time +/-1 SD (mins) | Mean number of procedures | Mean postoperative creatinine +/-SD (mg/dL) and time measured | Initial SFR% | Final SFR% | Definition | Failures (n) | Complications (n) | No. of Martin criteria met |
|---|---|---|---|---|---|---|---|---|---|
| Atis | 55.83 | 1.17 | 1.56 +/-0.50 | 83.3 | 95.8 | Fragments <4 mm | Failed to reach stone on second stage URS (1) | Febrile UTI (4) | 6 |
| Yuruk | 52.05 | 1.06 | 1.46 +/-0.51 | ND | 66.66 | ND | ND | Fever (1), haematuria (1), colicky pain (5) | 5 |
| Gao | 76.4 | 1.44 | 1.34 +/-0.71 | 64.44 | 93.33 | Fragments <2 mm | 60mm stone needed 4 URS sessions, PCNL contra indicated (1) | Transient elevation of creatinine (10), sepsis (2), AUR (2) | 6 |
| Giusti | 75.2 | 1.24 | 1.7 +/-0.6 | 72.4 | 93.1 | Fragments <2 mm | Residual stones <5 mm but asymptomatic (2) | Fever (4), AUR (1), haematuria (2), Steinstrasse causing anuria and acute renal inury | 6 |
ND = No Data
Nature of complication, frequency and Clavien grade (according to the papers)
| Nature of complication | Frequency | Clavien grade |
|---|---|---|
| Fever | 5 | I |
| Transient haematuria | 3 | I |
| Acute urinary retention | 3 | I |
| Transient elevation of creatinine | 10 | I |
| Urosepsis | 6 | II |
| Steinstrasse causing anuria and acute renal injury | 1 | III |
| Colicky pain | 5 | IIIa |
STROBE checklist for included studies (Y – yes, N – no, P – partial)
| Article section | STROBE checklist | Atis | Yuruk | Gao | Giusti | |
|---|---|---|---|---|---|---|
| Title and abstract | 1 | Indicate the study's design with a commonly used term in the title or the abstract | N | P | P | P |
| Provide in the abstract an informative and balanced summary of what was done and what was found | Y | Y | Y | Y | ||
| Introduction | ||||||
| Background | 2 | Explain the scientific background and rationale for the investigation being reported | Y | Y | Y | Y |
| Objectives | 3 | State specific objectives, including any pre-specified hypotheses | Y | Y | Y | P |
| Methods | ||||||
| Study design | 4 | Present key elements of study design early in the paper | Y | Y | Y | Y |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Y | Y | P | Y |
| Participants | 6 | Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | P | P | P | P |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | P | P | N | N |
| Data sources | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Y | Y | Y | Y |
| Bias | 9 | Describe any efforts to address potential sources of bias | N | N | N | N |
| Study size | 10 | Explain how the study size was arrived at | Y | Y | Y | Y |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | N | N | P | P |
| Statistical methods | 12 | Describe all statistical methods, including those used to control for confounding | Y | Y | Y | Y |
| Describe any methods used to examine subgroups and interactions | Y | Y | Y | N | ||
| Explain how missing data were addressed | N | N | N | N | ||
| If applicable, explain how loss to follow-up was addressed | N | N | N | N | ||
| Results | ||||||
| Participants | 13 | Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyse | N | N | N | N |
| Give reasons for non-participation at each stage | N | N | N | N | ||
| Consider use of a flow diagram | N | N | N | N | ||
| Descriptive data | 14 | Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | Y | Y | Y | Y |
| Indicate number of participants with missing data for each variable of interest | N | N | N | N | ||
| Summarise follow-up time (eg, average and total amount) | P | P | P | P | ||
| 15 | Report numbers of outcome events or summary measures over time | Y | Y | Y | Y | |
| 16 | Give unadjusted estimates and, if applicable, confounder- adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | N | N | N | N | |
| If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | N | N | N | N | ||
| 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Y | Y | Y | N | |
| Discussion | ||||||
| Key results | 18 | Summarise key results with reference to study objective | Y | Y | Y | Y |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Y | P | Y | P |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Y | Y | P | Y |
| Generalisabilty | 21 | Discuss the generalisability (external validity) of the study results | N | N | N | N |
| Other information | ||||||
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | N | N | N | N |
Martin criteria of complications (Y –yes, N – no)
| Martin criteria | Atis | Yuruk | Gao | Giusti |
|---|---|---|---|---|
| Method of accruing data defined | Y | Y | Y | Y |
| Duration of follow-up indicated | N | N | Y | Y |
| Outpatient information included | Y | N | Y | Y |
| Definition of complications provided | N | N | N | N |
| Mortality rate and causes of death listed | N | N | N | N |
| Morbidity rate and total complications indicated | Y | Y | Y | Y |
| Procedure-specific complications included | Y | Y | Y | Y |
| Severity grade utilised | Y | Y | Y | Y |
| Length-of-stay data | Y | Y | Y | Y |
| Risk factors included in the analysis | N | N | N | N |
| Total (n/10) | 6/10 | 5/10 | 7/10 | 7/10 |